Skip to main content
ACRV
NASDAQ Life Sciences

Q1 2026 Results: $7.3M ATM Offering Extends Cash Runway to Q3 2027 Amidst Clinical Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.98
Mkt Cap
$74.389M
52W Low
$1.05
52W High
$3.56
52W Position info
89% above low
Off High info
44% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ACRV sits 89% above its 52-week low of $1.05 on light trading volume (0.2× avg).

Summary

Acrivon Therapeutics reported Q1 2026 financial results, including a $19.0 million net loss, and announced a $7.3 million ATM offering in April 2026 that extends its cash runway into Q3 2027.


Key Events · Earnings and Guidance · ACRV

  • Q1 2026 Financial Results

    The company reported a net loss of $19.0 million for the three months ended March 31, 2026, a slight improvement from a $19.7 million net loss in the prior year period.

  • Cash Runway Extended to Q3 2027

    Existing cash, cash equivalents, and investments of $97.7 million as of March 31, 2026, combined with $7.3 million from a subsequent ATM offering, are expected to fund operations into the third quarter of 2027.

  • April 2026 ATM Offering Completed

    The company issued and sold 4,054,954 shares of common stock at $1.80 per share in April 2026, generating net proceeds of $7.3 million. This represents approximately 10.5% dilution based on shares outstanding at March 31, 2026.

  • Positive Clinical Pipeline Updates

    Acrivon reiterated positive clinical data for ACR-368 in endometrial cancer (52% cORR in serous EC) and ACR-2316 in small cell lung cancer (SCLC) and squamous non-small cell lung cancer (NSCLC), with both programs advancing.


Analysis · ACRV · Life Sciences

This quarterly report provides an update on Acrivon Therapeutics' financial health and clinical pipeline. The $7.3 million capital raise through an At-The-Market (ATM) offering, while dilutive, is a critical financing event that extends the company's operational runway into Q3 2027. This provides necessary funding for ongoing clinical trials for ACR-368 and ACR-2316, which continue to show positive data, and the advancement of new candidates like ACR-6840. The strategic move to bring diagnostic testing in-house also strengthens its precision medicine platform.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRV was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.4M. The 52-week trading range was $1.05 to $3.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRV - Latest Insights

ACRV
Nov 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.16 info
Change: +$0.010 (+0.87%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.16 info
Change: -$0.2731 (-19%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.16 info
Change: -$0.290 (-20%) info
Market Cap: $49.348M info
ACRV
Nov 16, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.16 info
Change: -$0.290 (-20%) info
Market Cap: $49.348M info
ACRV
Nov 10, 2026, 4:55 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.16 info
Change: -$0.440 (-28%) info
Market Cap: $49.348M info